Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

FMT and Fiber in Patients With Metabolic Syndrome (FMT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03727321
Recruitment Status : Recruiting
First Posted : November 1, 2018
Last Update Posted : November 1, 2018
Sponsor:
Collaborator:
The Weston A. Price Foundation
Information provided by (Responsible Party):
University of Alberta

Brief Summary:

This study is looking at the safety and effectiveness of stool transplant, also known as Fecal Microbiota Transplantation (FMT) and prebiotic supplementation in the management of metabolic syndrome.

Metabolic syndrome is a common progressive medical condition that is linked to obesity, diabetes, and heart disease. Obesity and metabolic syndrome are associated with abnormalities in gut flora which lead to chronic inflammation. This chronic inflammation is thought to worsen the insulin resistance and heart disease seen with metabolic syndrome. Current treatment strategies have shown limited effect, are expensive, and have side effects with long-term use.

FMT is a one-time treatment that has been shown to replace the abnormal gut flora and improve metabolic disease by increasing anti-inflammatory short chain fatty acid (SCFA) production. However, the effects from FMT are not permanent. Prebiotic supplementation is one strategy that may help to extend the benefits of FMT by helping sustain high SCFA levels. At this point, it is not known how FMT and prebiotics work together to affect SCFA levels in participants with metabolic syndrome.

This study will look at this interaction and answer if prebiotic therapy is effective in prolonging the benefits of FMT in participants with metabolic syndrome.


Condition or disease Intervention/treatment Phase
Obesity Metabolic Syndrome Combination Product: Fecal Microbial Transplant Dietary Supplement: Fiber Dietary Supplement: Cellulose Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 68 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Fecal Microbial Transplantation and Fiber Supplementation in Subjects With Obesity and Metabolic Syndrome
Actual Study Start Date : July 1, 2018
Estimated Primary Completion Date : March 1, 2020
Estimated Study Completion Date : March 1, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo: Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.
Dietary Supplement: Cellulose
Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.

Experimental: Fecal Microbial Transplant and cellulose
  1. Fecal Microbial Transplant - Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.
  2. Cellulose x 6weeks
Combination Product: Fecal Microbial Transplant
Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.
Other Name: FMT

Dietary Supplement: Cellulose
Placebo will consist of cellulose powder (Microcrystalline cellulose:Blanver) in foil packets.

Experimental: Fiber
Soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS).
Dietary Supplement: Fiber
A combination of soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), and Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS) for a total of 6 weeks (men 33g/day; women 27g/day)

Experimental: Fecal Microbial Transplant and Fiber
  1. Fecal Microbial Transplant
  2. Soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS).
Combination Product: Fecal Microbial Transplant
Fecal microbiome transplant (FMT): 50grams of FMT from a single, universal donor will be administered in 20-30 capsules taken by mouth.
Other Name: FMT

Dietary Supplement: Fiber
A combination of soluble corn fiber (PROMITOR®: Tate&Lyle), Resistant Wheat Starch 4 (Fibersym®: MGP Ingredients), and Acacia Gum (Pre-Hydrated Gum Arabic: TIC GUMS) for a total of 6 weeks (men 33g/day; women 27g/day)




Primary Outcome Measures :
  1. Insulin Sensitivity Assessment [ Time Frame: 12 weeks ]
    The homeostasis Model Assessment-Insulin Resistance (HOMA-IR) is a mathematical model to predict the interaction between glucose and insulin dynamics across a range of glucose plasma levels assuming a feedback circuit between the liver and β-cells in the pancreas


Secondary Outcome Measures :
  1. Health-related quality of life (HRQL): EQ-5D Index [ Time Frame: 12 week ]
    Assessment of the current health related quality of life will be accomplished by conducting standardized interviews and by using the validated questionnaires EQ-5D Index. Participants will report perceived health outcomes using this validated survey, and rank overall perceived health from 0 (low)- 100 (high).

  2. Dietary Intake [ Time Frame: 12 week ]
    Dietary intake will be assessed for each clinic using MyFitnessPal.

  3. Inflammatory markers [ Time Frame: 12 week ]
    . Levels of leptin, ghrelin, adiponectin, TNFα, IL-6, LPS (lipopolysaccharide), LPS-binding protein and zonulin will be determined using currently accepted laboratory techniques.

  4. Stool Microbiome [ Time Frame: 12 weeks ]
    Stool microbiome will be analyzed for Operational Taxonomic Unit determination.

  5. Anthropometric Measurements [ Time Frame: 12 weeks ]
    BMI (kg/m2)

  6. Fasting lipid profile [ Time Frame: 12 weeks ]
    Changes in Fasting lipid profile between baseline and 6 and 12 weeks

  7. Glucose Tolerance Assessment [ Time Frame: 12 weeks ]
    The oral glucose tolerance test (OGTT) is a dynamic test that reflects the efficiency of the body to dispose of glucose after an oral load. It is commonly used in clinical scenarios to diagnose glucose intolerance and diabetes. [33] After overnight fast (> 8 h), blood samples for determination of glucose and insulin concentration will be taken at -5, 0, 30, 60, and 120 min following a standard oral glucose load.

  8. Hunger and Satiety Assessment [ Time Frame: 12 weeks ]
    Assessed via the standardized hunger and satiety questionnaire (categorical variables with no analog scale)

  9. Gastrointestinal tolerance [ Time Frame: 12 weeks ]
    Assessed via the standardized gastrointestinal tolerance questionnaire (categorical variables with no analog scale)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • • Age ≥ 18 and < 65 years at the time of screening

    • BMI > 30
    • Total body weight fluctuation over the last 6 months less than 10%
    • Fasting plasma glucose > 5.6 mmol/L OR HgbA1c ≥5.5% OR patients receiving an antidiabetic medication
    • At least one of the following:

      • Fasting triglyceride ≥1.7 mmol/L OR receiving dyslipidemia medication
      • HDL cholesterol <1.03 mmol/L in males or <1.29 mmol/L in females OR receiving dyslipidemia medication
      • Known diagnosis of hypertension OR systolic blood pressure ≥130 or diastolic blood pressure ≥85 mmHg OR receiving antihypertension medication

Exclusion Criteria:

  • • Systolic blood pressure ≥180 or diastolic blood pressure ≥110 mmHg at screening.

    • Triglyceride ≥6 mmol/L.
    • Acute infectious or inflammatory condition over the presiding 4 weeks.
    • Current or recent use (Previous 6 months) of insulin for diabetes control.
    • History of oropharyngeal or significant esophageal dysphagia, inflammatory bowel disease, colon cancer, or colonic polyps with high grade dysplasia.
    • History of autoimmune conditions or chronic inflammatory condition, such as rheumatoid arthritis, chronic active hepatitis B or C, HIV, chronic pancreatitis, advanced NASH, or liver cirrhosis.
    • Active malignancy.
    • Active substance abuse or excessive EtOH (defined as >2 X 8oz drinks/d).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03727321


Contacts
Layout table for location contacts
Contact: Valentin Mocanu, MD 7809097109 vmocanu1987@gmail.com
Contact: Karen Madsen, PhD 7804925257 kmadsen@ualberta.ca

Locations
Layout table for location information
Canada, Alberta
Royal Alexandra Hospital Recruiting
Edmonton, Alberta, Canada, T5H 3V9
Contact: Valentin Mocanu, MD    7809097109    vmocanu1987@gmail.com   
Contact: Karen Madsen, PhD    7804925257    kmadsen@ualberta.ca   
University of Alberta Hospital Recruiting
Edmonton, Alberta, Canada, T6G 2B7
Contact: Valentin Mocanu, MD    7809097109    vmocanu1987@gmail.com   
Contact: Karen Madsen, PhD    7804925257    kmadsen@ualberta.ca   
Principal Investigator: Karen Madsen, PhD         
Sub-Investigator: Valentin Mocanu, MD         
Sponsors and Collaborators
University of Alberta
The Weston A. Price Foundation
Investigators
Layout table for investigator information
Principal Investigator: Karen Madsen, PhD University of Alberta
  Study Documents (Full-Text)

Documents provided by University of Alberta:

Layout table for additonal information
Responsible Party: University of Alberta
ClinicalTrials.gov Identifier: NCT03727321     History of Changes
Other Study ID Numbers: Pro00076642
First Posted: November 1, 2018    Key Record Dates
Last Update Posted: November 1, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: All individual participant data will be kept private and not distributed to other researchers outside of our study group. After the study is done, we will keep data stored for 25 years.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by University of Alberta:
Fecal microbial transplant
obesity
metabolic syndrome

Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Syndrome
Obesity
Disease
Pathologic Processes
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases